{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=56",
    "query": {
      "condition": "Diagnosis of Melanoma",
      "page": 56
    },
    "page_size": 10
  },
  "pagination": {
    "page": 56,
    "page_size": 10,
    "total_count": 1875,
    "total_pages": 188,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=57&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=55&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T03:12:25.271Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01624220",
      "title": "A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Tumor"
      ],
      "interventions": [
        {
          "name": "Spinal SBRT (Standard Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Spinal SBRT (Higher Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Gold Seed Implantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2012-08-03",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624220"
    },
    {
      "nct_id": "NCT00085306",
      "title": "Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Melanoma",
        "Recurrent Melanoma"
      ],
      "interventions": [
        {
          "name": "recombinant interferon beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2004-04",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-02",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085306"
    },
    {
      "nct_id": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Esophageal Squamous Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IIB Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIC Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Esophageal Carcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Hepatocellular Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Cutaneous Melanoma",
        "Metastatic Esophageal Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Esophageal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unresectable Cutaneous Melanoma",
        "Unresectable Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Home Health Encounter",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Monitoring",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-04-30",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265285"
    },
    {
      "nct_id": "NCT02062359",
      "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-02",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02062359"
    },
    {
      "nct_id": "NCT04728633",
      "title": "Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Liver",
        "Metastatic Uveal Melanoma",
        "Stage IV Choroidal and Ciliary Body Melanoma AJCC V8"
      ],
      "interventions": [
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Ethiodized Oil",
          "type": "DRUG"
        },
        {
          "name": "Transarterial Chemoembolization",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Device Usage and Evaluation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2021-09-27",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04728633"
    },
    {
      "nct_id": "NCT00055562",
      "title": "Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Melanoma",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "CC 5013",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2003-01",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055562"
    },
    {
      "nct_id": "NCT05013099",
      "title": "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Merkel Cell Carcinoma, Unspecified",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "zirconium Zr 89 crefmirlimab berdoxam",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImaginAb, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-12-09",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2024-07-22",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013099"
    },
    {
      "nct_id": "NCT00588198",
      "title": "Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 754,
      "start_date": "1991-10",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588198"
    },
    {
      "nct_id": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Melanoma",
        "Solid Tumor",
        "Squamous Cell Carcinoma of Head and Neck",
        "Breast Cancer",
        "Advanced Solid Tumor",
        "Triple Negative Breast Cancer",
        "Colorectal Carcinoma",
        "Non-melanoma Skin Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "ONCR-177",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Oncorus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2020-05-20",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348916"
    },
    {
      "nct_id": "NCT05094804",
      "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Tumor, Solid",
        "Malignant Neoplasm",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Leiomyosarcoma",
        "Liposarcoma"
      ],
      "interventions": [
        {
          "name": "OR2805",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoResponse, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2021-09-09",
      "completion_date": "2024-08-15",
      "has_results": false,
      "last_update_posted_date": "2023-11-02",
      "last_synced_at": "2026-11-19T03:12:25.271Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Austin, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05094804"
    }
  ]
}